Skip to main content

Table 2 Differences in quality of life trajectories between amyloid-positive and amyloid-negative SCD and MCI patients

From: A longitudinal study on quality of life along the spectrum of Alzheimer’s disease

  

EQ-5D utilities

VAS

Unadjusted

Model 1

Model 2

Model 3

Unadjusted

Model 1

Model 2

Model 3

Β (SE)

Β (SE)

Β (SE)

Β (SE)

Β (SE)

Β (SE)

Β (SE)

Β (SE)

SCD

positive

0.03 (0.02)

0.03 (0.02)

0.03 (0.02)

0.03 (0.02)

4.81 (2.02)*

4.57 (2.08)*

4.03 (2.05)*

4.06 (1.96)*

 

Time * positive

− 0.01 (0.004)*

− 0.01 (0.004)*

− 0.01 (0.004)*

− 0.01 (0.004)*

− 1.10 (0.45)*

− 1.08 (0.45)*

− 1.08 (0.45)*

− 0.96 (0.45)*

MCI

positive

0.10 (0.02)*

0.10 (0.02)*

0.09 (0.02)*

0.07 (0.21)*

7.68 (2.25)*

7.65 (2.32)*

6.01 (2.30)*

4.34 (2.32)

 

Time * positive

− 0.01 (0.004)*

− 0.01 (0.004)*

− 0.01 (0.004)*

− 0.01 (0.004)*

− 1.21 (0.44)*

− 1.19 (0.44)*

− 1.12 (0.44)*

− 1.07 (0.44)*

  1. Model 1: adjusted for age and sex
  2. Model 2: additionally adjusted for comorbidity score, education, squared education (only for EQ-5D models in MCI patients) and EQ-5D scale (EQ-5D only)
  3. Model 3: additionally adjusted for GDS
  4. *p < 0.05
  5. Of note: main effect of amyloid status represents the average difference between amyloid-positive and amyloid-negative patients at baseline; interaction effect represents the difference in QoL over time between amyloid-positive and amyloid-negative patients
  6. SCD subjective cognitive decline, MCI mild cognitive impairment, Aβ positive amyloid positive, SE standard error, GDS Geriatric Depression Scale